Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
ADC drugs, or Antibody-Drug Conjugates, are a class of pharmaceuticals formed by chemically linking small molecule drugs with biologically active antibodies.
With years of experience in protein, antibody, and ELISA kit development, CUSABIO can tailor products, services, and solutions to meet customer needs at various stages of ADC drug development.
mRNA vaccines represent a groundbreaking immunization technology harnessing the biological properties of messenger RNA (mRNA) to induce immune responses.
With years of expertise in protein, antibody, and ELISA kit development, CUSABIO possesses an extensive range of research reagents for viral studies and provides high-quality technical services. We are dedicated to supporting various stages of mRNA vaccine development, including early-stage research, production, quality control, and immune potency testing. Our commitment is to advance the progress of mRNA vaccine research.
Chimeric Antigen Receptor T (CAR-T) cell therapy is an individual cell-based technique that genetically treated T cells removed from patients in the lab and produce special receptors called chimeric antigen receptors, or CARs.
With years of expertise in protein, antibody, and ELISA kit development, CUSABIO possesses an extensive range of research reagents for viral studies and provides high-quality technical services. We are dedicated to supporting various stages of CAR-T cell therapy development, including CAR development, CAR-T preparation, CAR-T cell quality control and preclinical evaluation.
